Hartford Hospital
CAGE Code: 39AW3
NCAGE Code: 39AW3
Status: Active
Type: Commercial Supplier
Dun & Bradstreet (DUNS): 065533796
Summary
Hartford Hospital is an Active Commercial Supplier with the Cage Code 39AW3 and is tracked by Dun & Bradstreet under DUNS Number 065533796..
Address
80 Seymour St
Hartford CT 06106-3300
United States
Points of Contact
No Points of Contact...
Related Information
People who viewed this 'CAGE Code' also viewed...
Atlas Floor Machinery Corp Grainger Div Of W W Grainger Inc G C S Service, Inc Poly-Choke Co Inc General Medical Corp Fetkong Solutions Llc Jsb Group Freelancer Video Production J.V.C Service Llc Fuss & O'neill, Inc Dot A Code Plumbing Llc Bland Burner Co Clear Springs Honey Farm Llc Mjd Professional Cleaning Services Sign Designs And Banner Hoover Superior Ball Co Inc Sub Of Torbello Restoration, Llc Baumert Sales Co Inc Bess Computer Technology Skinner Grain & Fertilizer Co
Frequently Asked Questions (FAQ) for CAGE 39AW3
- What is CAGE Code 39AW3?
- 39AW3 is the unique identifier used by NATO Organizations to reference the physical entity known as Hartford Hospital located at 80 Seymour St, Hartford CT 06106-3300, United States.
- Who is CAGE Code 39AW3?
- 39AW3 refers to Hartford Hospital located at 80 Seymour St, Hartford CT 06106-3300, United States.
- Where is CAGE Code 39AW3 Located?
- CAGE Code 39AW3 is located in Hartford, CT, USA.
Contracting History for CAGE 39AW3 Most Recent 25 Records
- N6264523P2013
- Emergency Medical Simulation Training
- 21 Sep 2023
- Emergency Medical Simulation Training
- Naval Medical Logistics Command
- Department Of Defense (Dod)
- $85,026.50
- Department Of Defense (Dod)
- 75F40122C00130
- Ex Vivo Modeling, Simulation, And In Vivo Pharmacokinetic Validation To Guide Antimicrobial Dosing Recommendations For Patients On Continuous Renal Replacement Therapy
- 9 Sep 2022
- Ex Vivo Modeling, Simulation, And In Vivo Pharmacokinetic Validation To Guide Antimicrobial Dosing Recommendations For Patients On Continuous Renal Replacement Therapy
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $407,720.00
- Department Of Health And Human Services (Hhs)
- 75F40121C00128
- Eo14042 A Critical Look At Cefepime Breakpoints In Vivo An Assessment Of Cefepime Activity Against Carbapenemase-Producing Enterobacterales With Unexpected Cefepim -156.
- 30 Nov 2021
- Eo14042 A Critical Look At Cefepime Breakpoints In Vivo An Assessment Of Cefepime Activity Against Carbapenemase-Producing Enterobacterales With Unexpected Cefepim -156.
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $249,975.00
- Department Of Health And Human Services (Hhs)
- 75F40121C00184
- Despite The Recent Advancement In The Discovery And Development Of Novel Antibacterial Agents With High Efficacy For The Management Of Gram-Negative Infections, Treatments Options For Acinetobacter Baumannii Infections, Specifically, Those Due To
- 22 Sep 2021
- Despite The Recent Advancement In The Discovery And Development Of Novel Antibacterial Agents With High Efficacy For The Management Of Gram-Negative Infections, Treatments Options For Acinetobacter Baumannii Infections, Specifically, Those Due To
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $249,999.00
- Department Of Health And Human Services (Hhs)
- 75F40121C00128
- Modification To Include Hhsar Clause 352.270-5B Care Of Live Vertebrate Animals - A Critical Look At Cefepime Breakpoints In Vivo An Assessment Of Cefepime Activity.
- 8 Dec 2021
- Modification To Include Hhsar Clause 352.270-5B Care Of Live Vertebrate Animals - A Critical Look At Cefepime Breakpoints In Vivo An Assessment Of Cefepime Activity.
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $249,975.00
- Department Of Health And Human Services (Hhs)
- 75F40121C00128
- A Critical Look At Cefepime Breakpoints In Vivo An Assessment Of Cefepime Activity Against Carbapenemase-Producing Enterobacterales With Unexpected Cefepim -156.
- 28 Sep 2021
- A Critical Look At Cefepime Breakpoints In Vivo An Assessment Of Cefepime Activity Against Carbapenemase-Producing Enterobacterales With Unexpected Cefepim -156.
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $249,975.00
- Department Of Health And Human Services (Hhs)
- 75F40120C00164
- Eo14042 Metallo-B-Lactamase Resistance In Enterobacterales: Is It Time To Rethink Our In Vitro Assessment Tools?
- 10 Nov 2021
- Eo14042 Metallo-B-Lactamase Resistance In Enterobacterales: Is It Time To Rethink Our In Vitro Assessment Tools?
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $249,794.00
- Department Of Health And Human Services (Hhs)
- N6264518P2026
- Emergency Medical Simulation Training In Support Of Naval Undersea Medical Institute (Numi), Groton, Ct
- 26 Jul 2021
- Emergency Medical Simulation Training In Support Of Naval Undersea Medical Institute (Numi), Groton, Ct
- Naval Medical Logistics Command
- Department Of Defense (Dod)
- $482,279.00
- Department Of Defense (Dod)
- 75F40120C00164
- Metallo-B-Lactamase Resistance In Enterobacterales: Is It Time To Rethink Our In Vitro Assessment Tools?
- 20 Aug 2021
- Metallo-B-Lactamase Resistance In Enterobacterales: Is It Time To Rethink Our In Vitro Assessment Tools?
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $249,794.00
- Department Of Health And Human Services (Hhs)
- N6264518P2026
- Emergency Medical Simulation Training
- 28 Feb 2023
- Emergency Medical Simulation Training
- Naval Medical Logistics Command
- Department Of Defense (Dod)
- $539,764.16
- Department Of Defense (Dod)
- 75F40120C00164
- Metallo-B-Lactamase Resistance In Enterobacterales: Is It Time To Rethink Our In Vitro Assessment Tools?
- 18 Sep 2020
- Metallo-B-Lactamase Resistance In Enterobacterales: Is It Time To Rethink Our In Vitro Assessment Tools?
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $249,794.00
- Department Of Health And Human Services (Hhs)
- 75F40120C00171
- Baa Pharmacodynamics Of Minocycline, Levofloxacin, And Trimethoprim/Sulfamethoxazole Against Stenotrophomonas Maltophilia: Implications For Susceptibility Breakpoint Revisions
- 29 Sep 2020
- Baa Pharmacodynamics Of Minocycline, Levofloxacin, And Trimethoprim/Sulfamethoxazole Against Stenotrophomonas Maltophilia: Implications For Susceptibility Breakpoint Revisions
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $249,991.00
- Department Of Health And Human Services (Hhs)
- 75F40120C00171
- Baa Pharmacodynamics Of Minocycline, Levofloxacin, And Trimethoprim/Sulfamethoxazole Against Stenotrophomonas Maltophilia: Implications For Susceptibility Breakpoint Revisions
- 10 Aug 2021
- Baa Pharmacodynamics Of Minocycline, Levofloxacin, And Trimethoprim/Sulfamethoxazole Against Stenotrophomonas Maltophilia: Implications For Susceptibility Breakpoint Revisions
- Fda Office Of Acq Grant Svcs
- Department Of Health And Human Services (Hhs)
- $249,991.00
- Department Of Health And Human Services (Hhs)